Lizzy Lawrence,

Lizzy Lawrence is a medical devices reporter at STAT. She has experience writing about Silicon Valley workplaces and productivity tools for Protocol, local breaking news for the Baltimore Sun, and public health for Kaiser Health News. In 2020, she served as editor-in-chief of The Michigan Daily. Lizzy currently lives in Washington, D.C., but considers herself a New Yorker at heart.

Biography:  https://www.statnews.com/staff/lizzy-lawrence/

84%

The overall score is a weighted number that takes into account conflict of interest, bias, deception and other practices that undermines the credibility of the source. It is calculated as:
Analysis.OverallConflictOfInterestScore * 0.3F + Analysis.OverallBiasScore * 0.3F + Analysis.DeceptivenessScore * 0.3F + Analysis.ReadabilityScore * 0.1F

A score that takes into consideration the content for flow, interruptions with ads, and overt search engine optimization techniques that makes the content hard to understand

The Daily's Verdict

This author has a mixed reputation for journalistic standards. It is advisable to fact-check, scrutinize for bias, and check for conflicts of interest before relying on the author's reporting.

Bias

50%

Examples:

  • The biography provided does not mention any specific instances of bias in Lizzy Lawrence's reporting.

Conflicts of Interest

100%

Examples:

  • No specific conflicts of interest are mentioned in the articles or biography.

Contradictions

25%

Examples:

  • The article reports on the drop in shares of ResMed and Inspire after data release on late Friday, but no contradictory information is provided within the article itself.

Deceptions

100%

Examples:

  • No deceptive practices are identified in the article.

Recent Articles

New Drug Tirzepatide Shows Promise in Treating Obstructive Sleep Apnea, Reducing Need for CPAP Devices by 40-50%

New Drug Tirzepatide Shows Promise in Treating Obstructive Sleep Apnea, Reducing Need for CPAP Devices by 40-50%

Broke On: Tuesday, 25 June 2024 New clinical trials show that Eli Lilly's tirzepatide injection, used for diabetes and weight loss, significantly reduces sleep disruptions in obstructive sleep apnea patients. Up to 50% of trial participants no longer needed CPAP devices and experienced lower C-reactive protein levels, systolic blood pressure, and an average weight loss of 18%-20%. The SURMOUNT-OSA studies mark a major advancement in OSA treatment.